TABLE 1.
Diagnosis | 2020 | 2019 | P value |
Total – no. | 95 | 114 | |
ANCA GN – no. (%) | 15 (15.8) | 17 (14.9) | |
Acute interstitial nephritis – no. (%) | 9 (9.5) | 18 (15.8) | |
IgA nephropathy – no. (%) | 8 (8.4) | 10 (8.8) | |
Diabetic nephropathy – no. (%) | 7 (7.4) | 13 (11.4) | |
FSGS – no. (%) | 7 (7.4) | 15 (13.2) | |
Hypertensive nephropathy – no. (%) | 7 (7.4) | 9 (7.9) | |
Lupus nephritis – no. (%) | 7 (7.4) | 9 (7.9) | |
IgA vasculitis – no. (%) | 3 (3.2) | 2 (1.8) | |
Membranous GN – no. (%) | 3 (3.2) | 4 (3.5) | |
Postinfectious GN – no. (%) | 3 (3.2) | 1 (0,9) | |
Minimal change disease – no. (%) | 3 (3.2) | 1 (0,9) | |
Thrombotic microangiopathy – no. (%) | 2 (2.1) | 2 (1.8) | |
Amyloidosis – no. (%) | 2 (2.1) | 1 (0,9) | |
Monoclonal immune deposition disease – no. (%) | 2 (2.1) | 2 (1.8) | |
Others/not representative – no. (%) | 17 (17.9) | 10 (8.8) | 0.6532 |
Non-parametric between-group-comparisons were performed with Pearson’s Chi-square test. ANCA, anti-neutrophil cytoplasmic antibodies; BUN, blood urea nitrogen; CRP, C-reactive protein; FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; IgA, immunoglobulin A; IQR, interquartile range; No., number.